EP2124891A4 - Cilostazol enthaltende zubereitung mit kontrollierter freisetzung und verfahren zu ihrer herstellung - Google Patents

Cilostazol enthaltende zubereitung mit kontrollierter freisetzung und verfahren zu ihrer herstellung

Info

Publication number
EP2124891A4
EP2124891A4 EP08712523.3A EP08712523A EP2124891A4 EP 2124891 A4 EP2124891 A4 EP 2124891A4 EP 08712523 A EP08712523 A EP 08712523A EP 2124891 A4 EP2124891 A4 EP 2124891A4
Authority
EP
European Patent Office
Prior art keywords
preparation
cilostazoland
controlled release
preparation containing
release preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP08712523.3A
Other languages
English (en)
French (fr)
Other versions
EP2124891A1 (de
Inventor
Jin Woo Park
Kwang Hyun Shin
Min Jung Kwon
Joon Ho Bae
Do Yong Jeon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Pacific Pharmaceutical Co Ltd
Original Assignee
Amorepacific Corp
Pacific Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp, Pacific Pharmaceutical Co Ltd filed Critical Amorepacific Corp
Publication of EP2124891A1 publication Critical patent/EP2124891A1/de
Publication of EP2124891A4 publication Critical patent/EP2124891A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP08712523.3A 2007-02-16 2008-02-15 Cilostazol enthaltende zubereitung mit kontrollierter freisetzung und verfahren zu ihrer herstellung Withdrawn EP2124891A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070016352A KR20080076440A (ko) 2007-02-16 2007-02-16 실로스타졸의 제어방출 제제 및 그 제조방법
PCT/KR2008/000901 WO2008100106A1 (en) 2007-02-16 2008-02-15 Controlled release preparation containing cilostazoland process for the preparation thereof

Publications (2)

Publication Number Publication Date
EP2124891A1 EP2124891A1 (de) 2009-12-02
EP2124891A4 true EP2124891A4 (de) 2013-05-29

Family

ID=39690276

Family Applications (1)

Application Number Title Priority Date Filing Date
EP08712523.3A Withdrawn EP2124891A4 (de) 2007-02-16 2008-02-15 Cilostazol enthaltende zubereitung mit kontrollierter freisetzung und verfahren zu ihrer herstellung

Country Status (7)

Country Link
US (1) US20100136119A1 (de)
EP (1) EP2124891A4 (de)
JP (1) JP2010519200A (de)
KR (2) KR20080076440A (de)
CN (1) CN101631533B (de)
CA (1) CA2678482A1 (de)
WO (1) WO2008100106A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012500546A1 (en) * 2009-09-23 2017-04-19 Korea United Pharm Inc Slow-release cilostazol tablet having improved elution rate and minimal side effects
KR101068475B1 (ko) * 2009-12-29 2011-09-28 환인제약 주식회사 실로스타졸을 포함하는 서방성 제제 및 이의 제조방법
CN102133188B (zh) * 2011-03-18 2012-02-15 海南美兰史克制药有限公司 一种西洛他唑脂质体固体制剂
TWI615157B (zh) * 2013-02-06 2018-02-21 大塚製藥股份有限公司 包括不定形西洛他唑的固體分散劑
JP6078514B2 (ja) * 2014-10-30 2017-02-08 コリア ユナイテッド ファーム，インク 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠
US20160136282A1 (en) * 2014-11-18 2016-05-19 Genovate Biotechnology Co., Ltd. Novel formulation of cilostazol, a quinolinone-derivative used for alleviating the symptom of intermittent claudication in patients with peripheral vascular disease
JP6103111B1 (ja) * 2016-05-24 2017-03-29 三生医薬株式会社 経口医薬組成物及び該組成物からなる粒子状製剤の製造方法
JP6259043B2 (ja) * 2016-10-20 2018-01-10 コリア ユナイテッド ファーム，インク 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠
KR20200053746A (ko) * 2018-11-09 2020-05-19 (주)아모레퍼시픽 졸-겔 조성물
CN114533690B (zh) * 2022-03-22 2023-03-21 许昌市中心医院 含抗凝血药物西洛他唑的新制剂及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
WO2000057881A1 (en) * 1999-03-25 2000-10-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
US20020058066A1 (en) * 2000-09-22 2002-05-16 Otsuka Pharmaceutical Co., Ltd. Cilostazol dry coated tablet
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2006030301A1 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2208571A1 (en) * 1995-01-10 1996-07-18 Yuzo Kimura Resin particle, medical material and pharmaceutical preparation containing said resin particle
JP3799093B2 (ja) * 1995-01-10 2006-07-19 大塚製薬株式会社 樹脂粒状物およびこれを含有する医療製剤
JPH1067657A (ja) * 1996-06-18 1998-03-10 Otsuka Pharmaceut Co Ltd マルチプルユニット型持続性製剤
JP4748839B2 (ja) * 1999-03-25 2011-08-17 大塚製薬株式会社 シロスタゾール製剤
US8206738B2 (en) * 2001-05-01 2012-06-26 Corium International, Inc. Hydrogel compositions with an erodible backing member
IL162810A0 (en) * 2002-01-11 2005-11-20 Takeda Pharmaceutical coumarin derivatives, process for their productionand use thereof
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
KR20070021830A (ko) * 2005-08-20 2007-02-23 한국오츠카제약 주식회사 실로스타졸 및 아스피린 함유 서방정
KR20070024254A (ko) * 2005-08-26 2007-03-02 한국오츠카제약 주식회사 실로스타졸 함유 서방정

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997048382A2 (en) * 1996-06-18 1997-12-24 Otsuka Pharmaceutical Co., Ltd. Multiple-unit type prolonged action drug preparation
WO2000057881A1 (en) * 1999-03-25 2000-10-05 Otsuka Pharmaceutical Co., Ltd. Cilostazol preparation
US20020058066A1 (en) * 2000-09-22 2002-05-16 Otsuka Pharmaceutical Co., Ltd. Cilostazol dry coated tablet
WO2005023225A1 (en) * 2003-09-05 2005-03-17 Ranbaxy Laboratories Limited Cilostazol adsorbate
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2006030301A1 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Cilostazol- containing pharmaceutical composition based on particles of less than 50 micrometers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008100106A1 *

Also Published As

Publication number Publication date
JP2010519200A (ja) 2010-06-03
EP2124891A1 (de) 2009-12-02
WO2008100106A1 (en) 2008-08-21
US20100136119A1 (en) 2010-06-03
KR20090122344A (ko) 2009-11-27
CN101631533B (zh) 2012-08-22
CA2678482A1 (en) 2008-08-21
KR20080076440A (ko) 2008-08-20
CN101631533A (zh) 2010-01-20

Similar Documents

Publication Publication Date Title
ZA200905012B (en) Process for the preparation of certain substituted sulfimines
AP2577A (en) Process for preparing diaminophenothiazinium compounds
IL205253A (en) Processes for the preparation of tubolysines
EP2212248A4 (de) Verfahren zur herstellung von graphen
PT2345410T (pt) Composição farmacêutica para libertação modificada
ZA201007526B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
ZA201007983B (en) Process for the preparation of 2,3,3,3-tetrafluoropropene
EP2123631A4 (de) Verfahren zur herstellung von alkoxypropionamid
ZA200907191B (en) Process for the preparation of gefitiib
SI2151428T1 (sl) Postopek za pripravo agomelatina
GB0811007D0 (en) Process for makign crystals
PL2137206T3 (pl) Sposób wytwarzania kwasu tauroursodeoksycholowego
ZA201002442B (en) Process for preparing ethene
HU0700818D0 (en) Process for the preparation of polyirocyanates of the diphenylmethone series
IL184342A0 (en) Process for preparing ??-amino-??-hydroxycarboxamides
IL206530A0 (en) Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
EG26332A (en) Process for the preparation of benzonoprons
IL205082A0 (en) Process for the preparation of tetranorlabdane derivatives
PT2151429E (pt) Novo processo de síntese da agomelatina
GB0717102D0 (en) Process
IL202475A0 (en) Process for the preparation of aldehydes
GB2464854B (en) Process for the preparation of risperidone
ZA200907695B (en) Process for preparing dorzolam ide
ZA200907810B (en) Process for preparing valsartan
ZA201003264B (en) Method for the preparation of 2 chloro1,1,1,2,3,3,3 heptafluopropane

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090915

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130425

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/20 20060101ALI20130419BHEP

Ipc: A61K 9/10 20060101AFI20130419BHEP

Ipc: A61K 31/4709 20060101ALI20130419BHEP

Ipc: A61K 9/16 20060101ALI20130419BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20131126